HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.

AbstractPURPOSE:
Promising results of recent clinical trials with a triple drug bio-chemotherapy regimen encouraged its use in patients with renal cell carcinoma.
MATERIALS AND METHODS:
In a phase II study of patients with metastatic renal cell carcinoma the efficacy and toxicity of a treatment regimen were evaluated using interleukin-2 and interferon-alpha 2 subcutaneously in combination with intravenous 5-fluorouracil. The treatment protocol consisted of an 8-week cycle given on an outpatient basis, with 6 to 9 MU/m2. interferon-alpha given 1 to 3 times a week during the 8 weeks, and sequentially combined with 5 to 20 MU/m2. interleukin-2, 3 times a week for 4 weeks and 750 mg./m.2 5-fluorouracil once a week for 4 weeks.
RESULTS:
Among 25 consecutive men and 9 women treated 3 (9%) had a complete and 10 (29%) had a partial remission (overall objective response rate 38%). Median response duration (complete plus partial) was 12.5 months (range 3 to 20+). Stable disease lasting 3 to 24+ months was noted in 12 patients (35%). There were only minor side effects, for a maximum toxicity grade of I in 3 patients, II in 25 and III in 6 according to the World Health Organization classification. There were no dose limiting toxicities and no treatment related deaths.
CONCLUSIONS:
Triple drug immunochemotherapy resulted in a significant clinical effect comparable to an aggressive intravenous interleukin-2 treatment regimen but without significant toxicity.
AuthorsG Hofmockel, W Langer, M Theiss, A Gruss, H G Frohmüller
JournalThe Journal of urology (J Urol) Vol. 156 Issue 1 Pg. 18-21 (Jul 1996) ISSN: 0022-5347 [Print] United States
PMID8648791 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Interferon-alpha
  • Interleukin-2
  • Fluorouracil
Topics
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Renal Cell (secondary, therapy)
  • Combined Modality Therapy
  • Female
  • Fluorouracil (therapeutic use)
  • Follow-Up Studies
  • Humans
  • Interferon-alpha (therapeutic use)
  • Interleukin-2 (therapeutic use)
  • Kidney Neoplasms (pathology)
  • Male
  • Middle Aged
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: